MiSight® 1 day contact lenses are turning heads, including in mainstream media. Fortune magazine recently dubbed CooperVision “one to watch” in an article exploring MiSight® 1 day as a “purpose-built option” to both correct an age-appropriate* child’s vision and potentially slow the progression of their myopia.†[i]
Through interviews with eye care professionals, researchers and other industry experts, the article reveals several key takeaways including:
- MiSight® 1 day can be a practice builder and encourage referrals, according to MiSight® 1 day fitters Dr. Ashley Wallace-Tucker and Dr. Dave Anderson.
- Education is key. Growing parent awareness and understanding of childhood myopia and how it’s treated is an essential part of getting children with myopia the treatment they need.
- There’s more to come. There is still much to be done to address the myopia epidemic and CooperVision is dedicated to continued innovation.
With this article, Fortune joins The Wall Street Journal and Popular Science in highlighting MiSight® 1 day for mainstream audiences in the U.S. and beyond.
[i] Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.
*Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to 4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†Compared to a single vision 1 day lens over a 3-year period
